Endoscopic Injection Sclerotherapy Versus Endoscopic Band Ligation for Grade I-III Internal Hemorrhoids

Summary

This study is a prospective, multicentre, and randomized-controlled clinical study.The researchers wanted to explore the optimal treatment regimen for soft hemorrhoid within I-Ⅲ degrees by evaluating and comparing the effectiveness, safety and cost effect ratio of sclerosing injection and rubber lap ligation in patients with different internal hemorrhoid scores

Conditions

• Hemorrhoid
• Hemorrhoids
• Hemorrhoids Internal
• Hemorrhoid Prolapse
• Hemorrhoid Bleeding
• Hemorrhoid Pain

Interventions

OTHER

Endoscopic injection sclerotherapy

Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.

OTHER

Endoscopic Band Ligation

Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.

Sponsors & Collaborators

• First Affiliated Hospital of Zhejiang University

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• Wuhan Puren Hospital

  collaborator OTHER

• Yichang Central People's Hospital

  collaborator OTHER

• Fuyang Second People's Hospital

  collaborator UNKNOWN

• Hubei Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Shanxi Provincial Fifth People's Hospital

  collaborator UNKNOWN

• The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture

  collaborator OTHER

• Jingzhou First People's Hospital

  collaborator UNKNOWN

• Chibi People's Hospital

  collaborator UNKNOWN

• Tianyou Hospital Affiliated to Wuhan University of Science and Technology

  collaborator OTHER

• Central Hospital of Xiaogan

  collaborator OTHER

• Xiaogan First People's Hospital

  collaborator OTHER

• The First Affiliated Hospital of Army Medical University (Southwest Hospital)

  collaborator UNKNOWN

• Wuhan University of Science and Technology Affiliated Hanyang Hospital

  collaborator UNKNOWN

• Renmin Hospital of Wuhan University

  lead OTHER

Principal Investigators

• Mingkai Chen, M.D · Renmin Hospital of Wuhan University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-11-01

Primary Completion

2026-03-29

Completion

2026-03-29

Countries

• China

Study Locations